

FORM PTO 1390  
(REV 5-93)

US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NUMBER  
2002\_0319ATRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. §371U.S. APPLICATION NO.  
(if known, see 37 CFR 1.53)  
NEW 10/070921International Application No.  
PCT/JP00/06255International Filing Date  
September 13, 2000Priority Date Claimed  
September 13, 1999**Title of Invention**

METHOD FOR FINDING SUBSTANCE HAVING ANTI-INFLUENZA VIRUS ACTIVITY

**Applicant(s) For DO/EO/US**


Hiroshi KIDO and Meiko MURAKAMI

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (28 pages and 5 sheets of drawings) (35 U.S.C. §371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)).
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
- ☐ A translation of the amendments to the claims under PCT Article 19.
- ☒ An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). (unexecuted)
- ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).

**Items 11. to 14. below concern other document(s) or information included:**

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☒ Other items or information: (a) PCT Request (in Japanese); (b) Forms PCT/IB/301,304, 308 and 332; (c) International Search Report; (d) Published International Application (WO 01/20332); and (e) Forms PCT/IPEA/401, 402, 409 and 416.

U.S. APPLICATION NO. <b>10/070921</b> NEW		INTERNATIONAL APPLICATION NO. PCT/JP00/06255		ATTORNEY'S DOCKET NO. 2002 0319A					
15. [X] The following fees are submitted  <b>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee nor international search fee paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1040.00 International Search Report has been prepared by the EPO or JPO ..... \$ 890.00 International preliminary examination fee not paid to USPTO but international search paid to USPTO ..... \$ 740.00 International preliminary examination fee paid to USPTO but claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$ 690.00 International preliminary examination fee paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$ 100.00  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 50%;">CALCULATIONS</th> <th style="width: 50%;">PTO USE ONLY</th> </tr> <tr> <td style="height: 100px;"></td> <td></td> </tr> </table>		CALCULATIONS	PTO USE ONLY		
CALCULATIONS	PTO USE ONLY								
Surcharge of \$130.00 for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$					
Claims	Number Filed	Number Extra	Rate						
Total Claims	5 -20 =	0	X \$18.00	\$					
Independent Claims	1 - 3 =	0	X \$84.00	\$					
Multiple dependent claim(s) (if applicable)			+ \$280.00	\$					
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$890.00					
<input type="checkbox"/> Small Entity Status is hereby asserted. Above fees are reduced by 1/2.				\$					
<b>SUBTOTAL =</b>				\$890.00					
Processing fee of \$130.00 for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+					
<b>TOTAL NATIONAL FEE =</b>				\$890.00					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +				\$					
<b>TOTAL FEES ENCLOSED =</b>				\$890.00					
				Amount to be refunded					
				Amount to be charged					
a. [X] A check in the amount of \$890.00 to cover the above fees is enclosed. A duplicate copy of this form is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 23-0975 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0975.									
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b))          must be filed and granted to restore the application to pending status.</b>									
19. CORRESPONDENCE ADDRESS  <div style="text-align: center;">   <b>000513</b>          PATENT TRADEMARK OFFICE       </div>			By: <u>Michael R. Davis</u> Michael R. Davis, Registration No. 25,134  WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006-1021 Phone: (202) 721-8200 Fax: (202) 721-8250  March 13, 2002						

THE COMMISSIONER IS AUTHORIZED  
 TO CHARGE ANY DEFICIENCY IN THE  
 FEES FOR THIS PAPER TO DEPOSIT  
 ACCOUNT NO. 23-0975

[CHECK NO. 49315]  
 [2002\_0319A]

5/PRTB

10/070921

10/070921

JC10 Rec'd PCT/PTO 13 MAR 2002

## SPECIFICATION

### METHOD FOR FINDING SUBSTANCE

### HAVING ANTI-INFLUENZA VIRUS ACTIVITY

5

#### Technical Field

The present invention relates to a method for finding substances with anti-influenza virus activity.

#### Technical Background

10

There are basically three different approaches that have been taken in developing anti-influenza virus substances.

15

The first approach is to develop vaccines as anti-influenza virus substances. Vaccines such as inactivated influenza vaccines and live vaccines have been developed thus far.

20

The second approach is to find and develop channel blockers as anti-influenza virus substances that are targeted to  $M_2$  proteins in ion channels of influenza viruses.

The third approach is to find and develop anti-influenza virus substances that are targeted to sialic acids, which are found on the cell membrane and are known to serve as a receptor for influenza viruses upon infection.

25

However these approaches are accompanied by the

respective disadvantages such as follows.

In the first approach, which is directed to development of vaccines as anti-influenza virus substances, vaccines may not always be effective since surface  
5 glycoproteins of influenza virus, which are in many cases recognized as antigens, keep changing every year from one epidemic event to the next.

In regard of the second approach, which intends to find and develop channel blockers that are targeted to  $M_2$   
10 proteins in ion channels of influenza viruses, for example, Amantadine, which has traditionally been known as an effective treatment against Parkinson's disease and has proven to act as an  $M_2$  protein blocker, may exhibit strong side effects on the central nervous system and its use is  
15 currently restricted, making the substance inapplicable to all of the patients who suffer from influenza. Therefore, substances obtained through this approach may have the problem associated with the central nervous system.

In regard of the third approach, which intends to  
20 find and develop anti-influenza virus substances that are targeted to sialic acids, which are found on the cell membrane and are known to serve as a receptor for influenza viruses upon infection, substances obtained through this approach have yet to be fully exploited though they have  
25 been found to be effective. Further, this approach relies

on completely different sites of action and mechanism than those that the present invention takes advantage of.

# Disclosure of the Invention

5           The present invention has been devised to alleviate the above-described problems with the prior art and provides an effective approach for finding anti-influenza virus substances that act based on a different mechanism than that by which the prior art substances act.

10           During the course of our studies to understand the relationship between miniplasmin, and influenza virus and Sendai virus, the present inventors have found that miniplasmin is a key enzyme involved in the activation of influenza viruses, especially those that can cause acute or  
15. chronic pulmonary infection accompanied by infiltration of neutrophils. In other words, the present inventors have discovered that miniplasmin is an enzyme that plays a key role in the activation of influenza viruses or Sendai  
20 viruses and, in order for these viruses to become infectious in a human body, it is essential that miniplasmin should transform the viral structure into an active form.

          Based on these findings, the present inventors have reached the conclusion that developing a way to find  
25 miniplasmin inhibitors, substances that can block the

action of miniplasmin to activate influenza virus, will facilitate the search for anti-influenza virus substances for practical medical use.

Accordingly, one aspect of the present invention  
5 provides a method for finding anti-influenza virus substances that takes advantage of miniplasmin as a probe.

Another aspect of the present invention provides a method for finding anti-influenza virus substances, in which miniplasmin serving as the probe, and Sendai virus or  
10 influenza virus serving as a substrate are allowed to react with each other in the presence of a substance of interest. Subsequently, the amounts of subunits of a precursor of surface glycoproteins of the virus serving as the substrate in the reaction solution are used as indices for  
15 determining if the substrate of interest has anti-influenza virus activity.

Another aspect of the present invention provides a method for finding anti-influenza virus substances, in which miniplasmin serving as the probe, and Sendai virus or  
20 influenza virus serving as a substrate are allowed to react with each other in the presence of a substance of interest and subsequent to the reaction, the virus serving as the substrate is allowed to infect Mardin Darby canine kidney cells (referred to as MDCK cells, hereinafter) to obtain a  
25 cell infection unit as an index for determining if the

substrate of interest has anti-influenza virus activity.

The present inventors have observed that miniplasmin, an enzyme principally formed in a local region where a substantial neutrophil infiltration takes place because of a disease condition such as inflammation, is found attached to cell membranes in the local region, and when the cells are infected with influenza viruses, non-infectious influenza or Sendai viruses newly proliferating or budding from the infected cells are transformed, through the action of miniplasmin, into infectious viruses capable of infecting cells in the respiratory tract.

This finding led the present inventors to the idea that, by taking advantage of this characteristic of miniplasmin, a method for finding specific inhibitors of miniplasmin can be established, so that newly discovered drugs through such a method can be used to prevent the progress of influenza infection as represented by various inflammatory responses.

We shall now look into how we made these findings. As shown in Table 1, miniplasmin, produced either by elastase derived from human granulocytes or by elastase derived from a pig pancreas, is significantly more hydrophobic than plasmin and thus is more readily attached to the surfaces of various cell membranes. This observation led the present inventors to suspect

significant involvement of the enzyme in the protein cleavage, or transformation of the viruses into their infectious forms.

Influenza viruses and Sendai virus infect respiratory  
5 tracts to proliferate. Upon infection, hemagglutinin (HA),  
a precursor of surface glycoproteins in influenza viruses,  
must be cleaved into a hemagglutinin 1 (HA<sub>1</sub>) subunit and a  
hemagglutinin 2 (HA<sub>2</sub>) subunit, while a fusion protein (F<sub>0</sub>),  
a precursor of surface glycoproteins in Sendai virus, must  
10 be cleaved into a fusion protein 1 (F<sub>1</sub>) subunit and a  
fusion protein 2 (F<sub>2</sub>) subunit, by host's protease. This is  
because the viruses are not able to exhibit the ability to  
fuse cell membranes or the ability to infect cells unless  
the precursors of the surface glycoproteins are cleaved.

15 For this reason, we studied influenza viruses and  
Sendai virus, each representing the viruses of the kind  
that infects respiratory tracts, to see if miniplasmin was  
involved in the expression of the membrane-fusion ability  
and the infectivity of these viruses by being able to  
20 partially digest the surface glycoproteins of these viruses.  
The study revealed that miniplasmin was capable of  
partially digesting the surface glycoproteins of influenza  
viruses and Sendai virus, thereby making non-infectious  
viruses infectious.

25 The method of the present invention will now be

described.

First, a substance of interest that one wants to test for anti-influenza virus activity is added to a system including human miniplasmin and its substrate, for example, Sendai virus or influenza virus, and reactions are allowed to take place. Following the reaction, if influenza virus has been used to serve as the substrate, then the resulting products from the reaction vessel are analyzed for the presence of hemagglutinin 1 (HA<sub>1</sub>) and hemagglutinin 2 (HA<sub>2</sub>) subunits, which result from the cleavage of hemagglutinin (HA), a precursor of surface glycoproteins of influenza viruses. If Sendai virus has been used to serve as the substrate, then the products are analyzed for the presence of fusion protein 1 (F<sub>1</sub>) and fusion protein 2 (F<sub>2</sub>) subunits, which result from the cleavage of a fusion protein (F<sub>0</sub>), a precursor of surface glycoproteins of Sendai virus.

Presence of these subunits indicates that the human miniplasmin has exhibited the intended action, which proves that the substance of interest does not have anti-influenza virus activity, whereas absence of these subunits indicates that the action of human miniplasmin has been inhibited by the substance of interest, thereby proving the anti-influenza virus activity of the substance of interest.



In this manner, substances having anti-influenza virus activity can be found.

Aside from the above-described technique, MDCK cells may be infected with influenza virus and the cell infection unit (CIU) is counted to see if the action of human miniplasmin has been inhibited. In particular, a substance of interest that one wants to test for anti-influenza virus activity is added to a system including human plasmin and influenza virus to serve as the substrate, and reactions are allowed to proceed. Subsequently, influenza virus is collected from the reaction solution and is allowed to infect MDCK cells. The infected cells are detected with an anti-influenza antibody labeled with a fluorescent marker and the CIU is counted. If the CIU value obtained after the viruses have been allowed to react with miniplasmin to be activated in an experiment to which the substance of interest has been added is lower than that obtained in the control that does not include the substance of interest, the substance has been proved to have anti-influenza virus activity. In this manner, it is possible to determine whether if the substance of interest has anti-influenza virus activity.

When synthetic substrates such as those shown in Table 3 are used to serve as indices for finding miniplasmin inhibitors in the method of the invention, unlike the method in which a protein or an actual virus is employed to serve as the substrate, the inhibition rate may



**Table 1 COMPARISON BETWEEN PLASMIN AND MINIPLASMIN**

	Plasmin <sup>*1</sup>	Miniplasmin <sup>*2</sup>
Primary structure		
Molecular weight	90~94kDa (H chain + L chain)	38kDa (Kringles 5 + L chain)
Kringle structure	Kringle 1~5	Kringle 5
Hydrophobicity	-146.09 <sup>*2</sup>	-48.66 <sup>*2</sup>

\*1: human

\*2: hydrophobicity measured using the technique by Eisenberg *et al.*

**Table 2 SUBSTRATE SPECIFICITY OF HUMAN MINIPLASMIN**

Substrate	Activity (mU/ml)	% *
Boc-Gln-Ala-Arg-MCA	32.3	100.0
Boc-Leu-Thr-Arg-MCA	3.4	10.6
Boc-Phe-Ser-Arg-MCA	5.0	15.4
Boc-Val-Pro-Arg-MCA	5.0	15.4
Boc-Gln-Gly-Arg-MCA	8.1	25.0
Boc-Ala-Gly-Pro-Arg-MCA	2.5	7.7
Boc-Ile-Gln-Gly-Arg-MCA	1.6	4.8
Pro-Phe-Arg-MCA	5.0	15.4
Bz-Arg-MCA	0.0	0.0
Boc-Gln-Arg-Arg-MCA	16.1	50.0
Boc-Gly-Lys-Arg-MCA	3.1	9.6
Boc-Leu-Arg-Arg-MCA	3.1	9.6
Boc-Val-Leu-Lys-MCA	17.7	54.8
Boc-Glu-Lys-Lys-MCA	50.3	155.8
Suc-Leu-Leu-Val-Tyr-MCA	0.0	0.0
Suc-Ala-Ala-Pro-Phe-MCA	0.0	0.0

\* Activity as a percentage of that with Boc-Gln-Ala-Arg-MCA

Percent activity obtained for each substrate with respect to the activity for a fluorescent labeled synthetic substrate, Boc-Gln-Ala-Arg-MCA (100%). Synthetic substrates with particularly high specificity are shaded.

**Table 3 INHIBITOR SPECIFICITY OF HUMAN MINIPLASMIN**

Addition	Final concentration	Relative * activity
		%
None		100.0
○ Phenylmethylsulfonyl fluoride	1mM	95.1
	10mM	29.5
○ Diisopropylfluorophosphate	1mM	65.6
	10mM	3.3
⊙ Aprotinin	10 $\mu$ M	0.0
Anti-leuko protease	10 $\mu$ M	97.4
⊙ Leupeptin	10 $\mu$ M	18.6
Elastatinal	10 $\mu$ M	69.2
○ Benzamidine	10 $\mu$ M	67.6
	1mM	22.9
⊙ Kunitz-type soybean trypsin inhibitor	10 $\mu$ M	0.0
Cymostatin	10 $\mu$ M	100.0
⊙ Bowman-Birk soybean trypsin inhibitor	10 $\mu$ M	3.7
$\alpha_1$ -Antitrypsin	10 $\mu$ M	100.0
E-64	10 $\mu$ M	61.5
Pepstatin A	10 $\mu$ M	64.0
Phosphoramidon	10 $\mu$ M	100.0

\* Activity as a percentage of that with Boc-Glu-Lys-Lys-MCA

Percent inhibitor specificity obtained for each inhibitor with respect to the activity obtained for a synthetic substrate Boc-Glu-Lys-Lys-MCA (100%), which had the highest specificity toward the purified enzyme. A double circle indicates that the inhibitor exhibited strong inhibition. A circle indicates that the inhibitor exhibited increased inhibition at higher concentrations.

## Examples

### 1. Structure of human miniplasmin

Referring to Fig. 1, a result of SDS-polyacrylamide gel electrophoresis performed on purified human miniplasmin is shown. A single protein band appeared over the range from about 36kDa to 38kDa in the absence of reducing agent, whereas the miniplasmin was separated into two bands at 28kDa and at 12kDa in the presence of reducing agent. This indicates that miniplasmin includes the 28kDa protein and the 12kDa protein that are linked to one another through disulfide bonds. The protein bands at 28kDa and at 12kDa were transferred to a PVDF membrane, which was subjected to an amino acid sequence analysis to determine the amino acid sequence of each protein consisting of about 20 amino acid residues from the N-terminal. It was determined from this analysis that the protein band of 12kDa had the sequence of VVAPPPVLLPNVETPSEED- and the protein band of 28kDa had the sequence of VVGGCVAHPHSWP WDVSLRY-. Protein bands appeared again at 12kDa and 28kDa when miniplasmin was treated with elastase obtained from human granulocytes. These proteins proved to have precisely the same amino acid sequences as the previously-identified proteins.

These results suggest that as shown in Fig. 2, the 12kDa protein of human miniplasmin includes a kringle that begins with V<sup>441</sup> and the 28kDa protein includes a

microplasmin that begins with V<sup>561</sup>.

## 2. Characteristics of human miniplasmin

Miniplasmin obtained in the above-described manner has different characteristics as compared to plasmin. As shown in Table 1, miniplasmin lacks domains of kringle 1 to 4 (angiostatin) that are present on the N-terminal of plasmin and thus has a molecular weight of 38kDa, which is smaller than the molecular weight of plasmin of 94kDa. Miniplasmin also has a significantly higher hydrophobicity than plasmin and thus binds so securely to the surface of a cell membrane that it cannot be solubilized unless surfactants, such as NaCl solution with a concentration of 0.5M or higher or 0.5% Triton X (polyoxyethylene octylether manufactured by Sigma Co., Ltd.), are used.

Microplasmin, which has the same structure as miniplasmin except that it does not have kringle 5 of miniplasmin, becomes highly unstable at substantially neutral pHs and undergoes autolysis in a matter of minutes, resulting in the activity that is reduced by 50% or more from the initial activity. In contrast, the activity of miniplasmin can last as long as a few hours under the same conditions, though unstable.

## 3. Substrate specificity of human miniplasmin

The substrate specificity of human miniplasmin is shown in Table. 2. Among the different trypsin-type

proteases, miniplasmin showed the highest cleaving activity toward Boo-Glu-Lys-Lys-MCA, a synthetic substrate for plasmin. Miniplasmin also showed a considerably high cleaving activity toward a group of synthetic substrates, each of which included Glu(Glu)-X-Arg, the same type of amino acid sequence as the one that serves as a recognition site upon cleavage (cleavage motif) and is common among human influenza viruses reported thus far. Miniplasmin cut the bond after Arg.

In contrast, miniplasmin showed substantially no cleaving activity toward Boc-Ile-Gly-Arg-MCA, a synthetic substrate for factor Xa, which is one of the blood clotting factors and is also a protease with the activity similar to that of trypsin. Nor did it toward Bz-Arg-MCA, a synthetic substrate for cathepsin B, which is one of lysosomal enzymes.

#### 4. Inhibitor specificity of human miniplasmin

The inhibitor specificity of human miniplasmin is shown in Table 3. Among different protease inhibitors, aprotinin, which was derived from bovine lungs, a Kunitz-type soybean trypsin inhibitor and a Bowman-Birk trypsin inhibitor, each of which was derived from plants, showed strong inhibition against the protease activity of miniplasmin. In contrast, anti-leukoprotease (also known as MPI or SLPI), which inhibits activity of elastase and

trypsin, showed substantially no inhibition against the activity of miniplasmin. Benzamizine, diisopropylfluorophosphate, and phenylmethylsulfonyl fluoride, each of which inhibits activity of trypsin, showed strong inhibition when present at high concentrations of 1mM to 10mM.

#### 5. Activity of human miniplasmin to activate influenza viruses and Sendai virus

Non-infectious influenza virus and Sendai virus were labeled with [<sup>3</sup>H]-glucosamine and were treated with miniplasmin (1.5ig) for 15 minutes at 37 C and for 60 minutes at 37 C, respectively. As can be seen in Fig. 3, after the treatment, substantially all of HA of the influenza virus was degraded into HA<sub>1</sub> and HA<sub>2</sub> subunits, while about one-third of F<sub>0</sub> of the Sendai virus was degraded into F<sub>1</sub> and F<sub>2</sub> subunits. F<sub>0</sub> of the Sendai virus was completely degraded into F<sub>1</sub> and F<sub>2</sub> subunits by extending the treatment to as long as 3 hours (Fig. 5).

The influenza virus treated with miniplasmin was then allowed to infect MDCK cells, and the cell infection unit (CIU) was measured (Fig. 4). Specifically, non-infectious influenza A/Aichi/2/68(H3N2) strain was treated with different concentrations of miniplasmin at 37 C for 15 minutes in the presence of PBS and was then allowed to infect MDCK cells. The infected cells were detected with a

fluorescent-labeled anti-influenza A/Aichi/2/68(H3N2) antibody to count the CIU.

The CIU showed a significant increase as a function of the concentration of miniplasmin and reached a plateau at 10.4mU/ml. The activity of miniplasmin was quantified by defining the enzyme activity that can degrade 1 $\mu$ mol of the synthetic substrate Boc-Glu-Ala-Arg-MCA in 1 minute as 1 unit.

The results indicate that human miniplasmin has activity to transform non-infectious influenza virus and Sendai virus into their infectious forms.

#### Brief Description of the Drawings

Fig. 1 is a result of SDS-PAGE performed on human miniplasmin: lane 1, molecular weight marker; lane 2, human miniplasmin (0.2 $\mu$ g); lane 3, molecular weight marker; and lane 4, human miniplasmin (0.2 $\mu$ g).

All lanes were subsequently silver-stained with the lanes 1 and 2 electrophoresed under non-reducing conditions and the lanes 3 and 4 under reducing conditions.

Molecular weight markers: rabbit muscle phospholase B (97.2kDa); BSA (66.4kDa); ovalmin(45.0kDa); carbonic anhydrase (29.0kDa); soybean trypsin inhibitor (20.1kDa); and lysozyme (14.3kDa).

Fig. 2 shows the primary structure of human

plasminogen and human miniplasmin: human plasminogen  
(residue 1-790) and miniplasmin (residue 441-790) are shown.

Fig. 3 is a result of electrophoresis showing the  
manner in which miniplasmin partially digests an HA protein  
5 of influenza A/Aichi/2/68 and an F<sub>0</sub> protein of Sendai virus.

Lane 1: [<sup>3</sup>H]Glucosamine-labeled Influenza virus  
A/Aichi/2/68,

Lane 2: [<sup>3</sup>H]Glucosamine-labeled Influenza virus  
A/Aichi/2/68 + miniplasmin (1.5ig), incubated for 15min. at  
10 37 C,

Lane 3: [<sup>3</sup>H]Glucosamine-labeled Sendai virus,

Lane 4: [<sup>3</sup>H]Glucosamine-labeled Sendai virus +  
miniplasmin (1.5ig), incubated for 60min. at 37 C.

Fig. 4 is a graph showing the manner in which  
15 miniplasmin causes transformation of non-infectious  
influenza A/Aichi/2/68(H3N2) into its infectious form, and  
inhibition of the transformation by aprotinin.

Non-infectious influenza virus A/Aichi/2/68(H3N2) was  
treated either with different concentrations of miniplasmin  
20 (solid circles), or with 20mU/ml miniplasmin to which  
aprotinin has been added to a final concentration of 1iM  
(hollow squares), for 15 minutes at 37 C and was then  
allowed to infect MDCK cells. 10 hours after the infection,  
the infected cells were detected with a fluorescent(FITC)-  
25 labeled anti-influenza A/Aichi antibody.

inhibitor specificity of miniplasmin, in which [ $^3\text{H}$ ]-labeled Sendai virus was used as a substrate for the purified enzyme to see the effects of various inhibitors.

5

Final concentration  
( $\mu\text{M}$ )

- 0 : [ $^3\text{H}$ ]-labeled Sendai virus
- 0' : [ $^3\text{H}$ ]-labeled Sendai virus + purified enzyme
- 10 1 : [ $^3\text{H}$ ]-labeled Sendai virus + purified enzyme + PMSF  
1mM
- 2 : [ $^3\text{H}$ ]-labeled Sendai virus + purified enzyme + DFP  
1mM
- 3 : [ $^3\text{H}$ ]-labeled Sendai virus + purified enzyme + Aprotinin  
15 1 $\mu\text{M}$
- 4 : [ $^3\text{H}$ ]-labeled Sendai virus + purified enzyme + Anti-leuko protease  
1 $\mu\text{M}$
- 5 : [ $^3\text{H}$ ]-labeled Sendai virus + purified enzyme + Leupeptin  
1 $\mu\text{M}$
- 20 6 : [ $^3\text{H}$ ]-labeled Sendai virus + purified enzyme + Elastatinal  
1 $\mu\text{M}$
- 7 : [ $^3\text{H}$ ]-labeled Sendai virus + purified enzyme + Benzamidine  
1 $\mu\text{M}$
- 8 : [ $^3\text{H}$ ]-labeled Sendai virus + purified enzyme + Knitz-type soybean trypsin inhibitor  
25 1 $\mu\text{M}$

9 : [<sup>3</sup>H]-labeled Sendai virus + purified enzyme + O-phenanthlorin 1iM  
 10: [<sup>3</sup>H]-labeled Sendai virus + purified enzyme + Chymostatin 1iM

5

# Best Modes for Carrying out the Invention

## Reference Example 1 Preparation of human miniplasmin from human plasmin

1mg of human plasmin (Sigma) and 3ig of elastase  
 10 extracted from a pig pancreas were dissolved in a 50mM Tris-HCl buffer solution (pH8.0). Reactions were allowed to proceed for 3 hours and 15 minutes while being agitated. After the reaction period, elastatinal was added to a final concentration of 50iM. Reactions were allowed to proceed  
 15 for another 30 minutes at room temperature while being agitated. After the reaction period, a buffer containing NaCl was added to give a final concentration of 50mM Tris-HCl buffer (pH8.0)/0.5M NaCl. The reaction solution was centrifuged for 30 minutes at 14,000xg. Subsequently, the  
 20 supernatant was loaded onto a soybean trypsin inhibitor sepharose 4B column to allow miniplasmin to be adsorbed onto the medium. The column was thoroughly washed and the adsorbed miniplasmin was then eluted with 50mM glycine-HCl buffer (pH2.8)/0.5M NaCl. The eluate was loaded onto a gel  
 25 filtration HPLC column (Superdex 200, trade name,

manufactured by Amersham Pharmacia Biotech Co., Ltd.) to remove impurities. This resulted in a final product.

Reference Example 2 Preparation of human miniplasmin from human plasmin

5           1mg of human plasmin (Sigma) and 3ig of elastase extracted from human granulocytes were dissolved in a 50mM Tris-HCl buffer solution(pH8.0). Reactions were allowed to proceed for 3 hours and 15 minutes while being agitated. After the reaction period, elastatinal was added to a final  
10           concentration of 50iM. Reactions were allowed to proceed for another 30 minutes at room temperature while being agitated. After the reaction period, a buffer containing NaCl was added to give a final concentration of 50mM Tris-HCl buffer (pH8.0)/0.5M NaCl. The reaction solution was  
15           centrifuged for 30 minutes at 14,000xg. Subsequently, the supernatant was loaded onto a soybean trypsin inhibitor sepharose 4B column to allow miniplasmin to be adsorbed onto the medium. The column was thoroughly washed and the adsorbed miniplasmin was then eluted with 50mM glycine-HCl  
20           buffer (pH2.8)/0.5M NaCl. The eluate was loaded onto a gel filtration HPLC column (Superdex 200, trade name, manufactured by Amersham Pharmacia Biotech Co., Ltd.) to remove impurities. This resulted in a final product.

Example 1

25           First, [<sup>3</sup>H]-labeled Sendai virus was treated with



development/fixation to detect bands of  $F_0$ ,  $F_1$  and  $F_2$ .

The results showed that transformation of  $F_0$  into  $F_1$  and  $F_2$  was substantially prevented by diisopropylfluorophosphate. Accordingly,

5 diisopropylfluorophosphate has been shown to be an inhibitor of miniplasmin.

#### Example 2

1  $11\text{M}$  of aprotinin was added to the same system as in Example 1 and reactions were allowed to proceed at  $37^\circ\text{C}$  for  
10 3 hours. Subsequently, the presence of  $F_1$  and  $F_2$  subunits in the system was determined in the same manner as described in Example 1.

The results indicated that transformation of  $F_0$  into  $F_1$  and  $F_2$  was substantially prevented by aprotinin.  
15 Accordingly, aprotinin has been shown to be an inhibitor of miniplasmin.

#### Example 3

20  $11\text{M}$  of benzamidine was added to the same system as in Example 1 and reactions were allowed to proceed at  $37^\circ\text{C}$  for 3 hours. Subsequently, the presence of  $F_1$  and  $F_2$  subunits in the system was determined in the same manner as described in Example 1.

The results indicated that transformation of  $F_0$  into  $F_1$  and  $F_2$  was substantially prevented by benzamidine.  
25 Accordingly, benzamidine has been shown to be an inhibitor

of miniplasmin.

#### Example 4

11M of Kunitz-type soybean trypsin inhibitor was added to the same system as in Example 1 and reactions were allowed to proceed at 37 C for 3 hours. Subsequently, the presence of F<sub>1</sub> and F<sub>2</sub> subunits in the system was determined in the same manner as described in Example 1.

The results indicated that transformation of F<sub>0</sub> into F<sub>1</sub> and F<sub>2</sub> was substantially prevented by Kunitz-type soybean trypsin inhibitor. Accordingly, Kunitz-type soybean trypsin inhibitor has been shown to be an inhibitor of miniplastin.

#### Example 5

First, non-infectious influenza A/Aichi/2/68 (H3N2) strain was treated with miniplasmin (944mU/mg) at concentrations of 0, 1.2, 5.2, 10.4, and 52mU/ml in the presence of PBS at 37 C for 15 minutes. Subsequently, the virus was allowed to infect MDCK cells and infected cells were detected with a fluorescent-labeled anti-influenza A/Aichi/2/68 (H3N2) antibody to count the CIUs. The obtained CIUs for the respective concentrations were 0(undetectable),  $1 \times 10^6$ ,  $1.3 \times 10^7$ ,  $7.5 \times 10^7$  and  $9.6 \times 10^7$  CIU.

Next, 11M aprotinin was added to the system in which plasmin concentration was sufficiently high (10.4mU/mL) to cause the infectivity plateau, and reactions were allowed

to proceed for 15 minutes. The CIU was counted in the same manner as described above.

The CIU after the treatment with 11M aprotinin was determined to be  $3.7 \times 10^3$  CIU. Given the fact that the CIU  
5 obtained for the virus activated by miniplasmin in the experiment without any of the substances of interest was  $7.5 \times 10^7$ , it has been proven that aprotinin has caused the decrease in the CIU and substantially prevented the transformation of non-infectious influenza virus into  
10 infectious virus.

#### Industrial Applicability

The present invention makes it possible to efficiently find substances with anti-influenza virus  
15 activity *in vitro* by employing miniplasmin as a probe.

## Claims

1. A method for finding a substance with anti-influenza virus activity, the method being characterized in  
5 that miniplasmin is used as a probe.

2. The method for finding a substance with anti-influenza virus activity according to claim 1, characterized in that miniplasmin serving as the probe and Sendai virus serving as a substrate are allowed to react  
10 with each other in the presence of a substance of interest, such that subsequent to the reaction, amounts of a fusion protein 1 (F<sub>1</sub>) subunit and a fusion protein 2 (F<sub>2</sub>) subunit of Sendai virus that are present in a reaction solution are used as indices for determining if the substrate of  
15 interest has anti-influenza virus activity.

3. The method for finding a substance with anti-influenza virus activity according to claim 1, characterized in that miniplasmin serving as the probe and influenza virus serving as a substrate are allowed to react  
20 with each other in the presence of a substance of interest, such that subsequent to the reaction, amounts of a hemagglutinin 1(HA<sub>1</sub>) subunit and a hemagglutinin 2(HA<sub>2</sub>) subunit of influenza virus that are present in a reaction solution are used as indices for determining if the  
25 substrate of interest has anti-influenza virus activity.

4. The method for finding a substance with anti-influenza virus activity according to claim 1, characterized in that miniplasmin serving as the probe and Sendai virus serving as a substrate are allowed to react with each other in the presence of a substance of interest and subsequent to the reaction, the Sendai virus is allowed to infect MDCK cells to obtain a cell infection unit as an index for determining if the substrate of interest has anti-influenza virus activity.


5. The method for finding a substance with anti-influenza virus activity according to claim 1, characterized in that miniplasmin serving as the probe and influenza virus serving as a substrate are allowed to react with each other in the presence of a substance of interest and subsequent to the reaction, influenza virus is allowed to infect MDCK cells to obtain a cell infection unit as an index for determining if the substrate of interest has anti-influenza virus activity.

[illegible]

5

10

FIG.1



10/070921





FIG.2

Influenza A/Aichi/2/68



Sendai virus





FIG.3

FIG.4






FIG.5

## DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

☐ Original ☐ Supplemental ☐ Substitute ☒ PCT ☐ DESIGN

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: METHOD FOR FINDING SUBSTANCE HAVING ANTI-INFLUENZA VIRUS ACTIVITY

of which is described and claimed in:

☐ the attached specification, or  
☐ the specification in application Serial No. \_\_, filed \_\_, and with amendments through \_\_, or  
☒ the specification in International Application No. PCT/JP00/06255, filed September 13, 2000, and as amended on \_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Japan	11-259372	September 13, 1999	yes


I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

62 And I hereby appoint Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Warren M. Check, Jr., Reg. No. 33,367; Nils Pedersen, Reg. No. 33,145; Charles R. Watts, Reg. No. 33,142; and Michael S. Huppert, Reg. No. 40,268, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., as well as any other attorneys and agents associated with Customer No. 000513, to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys and agents named herein to accept and follow instructions from K.K. Hikari Jimusyo as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

# 000000000000 - 000000000000

Direct Correspondence to Customer No:  <b>000513</b> PATENT TRADEMARK OFFICE		Direct Telephone Calls to:  WENDEROTH, LIND & PONACK, L L P 2033 "K" Street, N W , Suite 800 Washington, D C 20006-1021  Phone (202) 721-8200 Fax (202) 721-8250	
--	--	---	--

<b>1-00</b> Full Name of First Inventor	FAMILY NAME <b>KIDO</b>		FIRST GIVEN NAME <b>Hiroshi</b>		SECOND GIVEN NAME	
	CITY <b>Tokushima</b>		STATE OR COUNTRY <b>Japan</b>		COUNTRY OF CITIZENSHIP <b>Japan JPX</b>	
	ADDRESS <b>11-10, Higashi Yoshino-cho 3-chome, Tokushima-shi, Tokushima 770-0811 Japan</b>		CITY		STATE OR COUNTRY ZIP CODE	

<b>2-00</b> Full Name of Second Inventor	FAMILY NAME <b>MURAKAMI</b>		FIRST GIVEN NAME <b>Meiko</b>		SECOND GIVEN NAME	
	CITY <b>Tokushima</b>		STATE OR COUNTRY <b>Japan</b>		COUNTRY OF CITIZENSHIP <b>Japan JPX</b>	
	ADDRESS <b>38, Minami Shoumachi 2-chome, Tokushima-shi, Tokushima 770-0045 Japan</b>		CITY		STATE OR COUNTRY ZIP CODE	

Full Name of Third Inventor	FAMILY NAME		FIRST GIVEN NAME		SECOND GIVEN NAME	
	CITY		STATE OR COUNTRY		COUNTRY OF CITIZENSHIP	
	ADDRESS		CITY		STATE OR COUNTRY ZIP CODE	

Full Name of Fourth Inventor	FAMILY NAME		FIRST GIVEN NAME		SECOND GIVEN NAME	
	CITY		STATE OR COUNTRY		COUNTRY OF CITIZENSHIP	
	ADDRESS		CITY		STATE OR COUNTRY ZIP CODE	

Full Name of Fifth Inventor	FAMILY NAME		FIRST GIVEN NAME		SECOND GIVEN NAME	
	CITY		STATE OR COUNTRY		COUNTRY OF CITIZENSHIP	
	ADDRESS		CITY		STATE OR COUNTRY ZIP CODE	

Full Name of Sixth Inventor	FAMILY NAME		FIRST GIVEN NAME		SECOND GIVEN NAME	
	CITY		STATE OR COUNTRY		COUNTRY OF CITIZENSHIP	
	ADDRESS		CITY		STATE OR COUNTRY ZIP CODE	

Post Office Address	ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
------------------------	---------	------	------------------	----------

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor Hiroshi Kido Hiroshi KIDO Date March 18, 2002  
 2nd Inventor Meiko Murakami Meiko MURAKAMI Date March 18, 2002  
 3rd Inventor \_\_\_\_\_ Date \_\_\_\_\_  
 4th Inventor \_\_\_\_\_ Date \_\_\_\_\_  
 5th Inventor \_\_\_\_\_ Date \_\_\_\_\_  
 6th Inventor \_\_\_\_\_ Date \_\_\_\_\_

The above application may be more particularly identified as follows:

U.S. Application Serial No. 10/070,921 Filing Date March 13, 2002

Applicant Reference Number PCTF0008-US Atty Docket No. 2002\_0319A

Title of Invention METHOD FOR FINDING SUBSTANCE HAVING ANTI-INFLUENZA VIRUS ACTIVITY